{"disease":{"id":"cp-cml-with-resistance-or-intolerance","name":"cp cml with resistance or intolerance"},"drugs":{"marketed":[{"drug_id":"ponatinib-hydrochloride","indication_name":"CP-CML with resistance or intolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PONATINIB HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Ponatinib inhibits multiple kinases, including ABL and its T315I mutant, reducing tumor size in mice."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}